- Home
- CCI vs ARGX Comparison
CCI vs ARGX Comparison
Compare CCI & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCI
- ARGX
- Stock Information
- Founded
- CCI 1994
- ARGX 2008
- Country
- CCI United States
- ARGX Netherlands
- Employees
- CCI N/A
- ARGX N/A
- Industry
- CCI Real Estate Investment Trusts
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCI Real Estate
- ARGX Health Care
- Exchange
- CCI Nasdaq
- ARGX Nasdaq
- Market Cap
- CCI 43.6B
- ARGX 40.4B
- IPO Year
- CCI 1998
- ARGX 2017
- Fundamental
- Price
- CCI $102.35
- ARGX $565.63
- Analyst Decision
- CCI Buy
- ARGX Strong Buy
- Analyst Count
- CCI 20
- ARGX 20
- Target Price
- CCI $116.95
- ARGX $698.22
- AVG Volume (30 Days)
- CCI 3.0M
- ARGX 464.4K
- Earning Date
- CCI 04-30-2025
- ARGX 05-08-2025
- Dividend Yield
- CCI 6.12%
- ARGX N/A
- EPS Growth
- CCI N/A
- ARGX N/A
- EPS
- CCI N/A
- ARGX 15.94
- Revenue
- CCI $6,515,000,000.00
- ARGX $2,643,062,000.00
- Revenue This Year
- CCI N/A
- ARGX $61.64
- Revenue Next Year
- CCI $3.20
- ARGX $32.00
- P/E Ratio
- CCI N/A
- ARGX $31.18
- Revenue Growth
- CCI 3.05
- ARGX 82.13
- 52 Week Low
- CCI $84.20
- ARGX $352.77
- 52 Week High
- CCI $120.92
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- CCI 50.81
- ARGX 44.12
- Support Level
- CCI $97.07
- ARGX $530.97
- Resistance Level
- CCI $105.54
- ARGX $578.26
- Average True Range (ATR)
- CCI 2.31
- ARGX 20.41
- MACD
- CCI -0.59
- ARGX -7.47
- Stochastic Oscillator
- CCI 49.91
- ARGX 28.13
About CCI Crown Castle Inc.
Crown Castle owns and leases roughly 40,000 cell towers in the United States. It also owns more than 90,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. Crown Castle's towers and fiber are predominantly in the largest US cities. The company has a very concentrated customer base, with about 75% of its revenue from the Big Three US mobile carriers. Crown Castle operates as a real estate investment trust. It has announced plans to divest its fiber business, which should be finalized in 2026. After that, Crown will be a stand-alone tower operator.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.